Skip to NavigationSkip to content

Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies

Published on 10/07/19 at 10:33am

Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to remedy the nation’s shortage of the potentially life-saving drug.

The shortage, which has now gone on for an entire year, hinges on the availability of Mylan’s EpiPen, the most common and well-known version of the drug, in what the FDA has characterised as “manufacturing delays”. The problem, according to Mylan, lies at the feet of Meridian Medical Technologies, a Pfizer subsidiary that manufactures the devices.

In response to the ongoing shortage, Novartis’ Sandoz unit made its Symjepi auto-injector available to hospitals in January, but now is extending that availability to pharmacies, as part of a commercialisation agreement with Adamis Pharmaceuticals Corp. The price for a two-pack is $250 – $50 cheaper than Mylan’s own generic version of its flagship product.  

According to Pfizer, the ongoing shortage should be expected to continue over the coming months.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches